IRVINE, Calif., Jan. 30, 2019 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading
temperature-controlled logistics company dedicated to the life
sciences industry, today will celebrate the official opening of its
most recent Global Logistics Center, based in Amsterdam, The Netherlands. The ribbon-cutting
ceremony will be attended by Cryoport clients, governmental
dignitaries and business partners. The new Global Logistics Center
is located at Parellaan 18, 2132 WS Hoofddorp, near the Schiphol
Amsterdam Airport, which serves as The Netherland's main aviation
hub for international air traffic.
Opening this new state-of-the-art Global Logistics Center in
Amsterdam strategically adds to
Cryoport's global network supporting the distribution of
biopharmaceutical products requiring exacting temperature and
condition controls. Cryoport's "Chain of Compliance™" processes
will be employed at the new facility, which was built so that it
can be rapidly scaled to support additional demand for services.
Cryoport clients, including Gilead Sciences, Novartis, Bellicum
Pharmaceuticals, Immatics, Janssen Pharmaceuticals, and others,
will benefit from Cryoport's new Global Logistics Center.
Amsterdam is a world-leading
hub for the life sciences industry as a result of the region's many
cutting-edge researchers, startups and collaborations, favorable
import and export environment, and significant transit
infrastructure. In January 2019, the
European Medicines Agency moved its headquarters to Amsterdam, joining other major institutes
including The Netherlands Cancer Institute and the Sanquin Blood
Supply Foundation. Amsterdam
supports the life sciences industry in many ways including the
Amsterdam Science Park, an incubator for the development of
healthcare businesses and special support of areas around the
Schiphol Amsterdam Airport and the Port of Amsterdam, which offers strategic logistics
hub locations.
Jerrell Shelton, Chief Executive
Officer of Cryoport, commented, "The demand for comprehensive
global support of regenerative therapies is growing rapidly. We are
happy to add Amsterdam to our
global network with its excellent connectivity and reputation as
one of Europe's leading life
sciences hubs. Choosing this strategic locating for our newest
Global Logistics Center allows us to more effectively support
our global biopharmaceutical client base throughout the research,
clinical and commercialization phases of their revolutionary
regenerative therapies. We would also like to thank the Dutch
regulatory officials who worked so effectively to accommodate and
welcome us to Amsterdam."
About Cryoport, Inc.
Cryoport is a trusted global
provider of temperature controlled logistics solutions for life
sciences commodities during distribution, serving the
biopharmaceutical market with leading-edge logistics solutions for
biologic materials, such as regenerative medicine, including
immunotherapies, stem cells and CAR-T cells. Cryoport's solutions
are used by points-of-care, CRO's, central laboratories,
pharmaceutical companies, manufacturers, university researchers et
al; as well as the reproductive medicine market, primarily in IVF
and surrogacy; and the animal health market, primarily in the areas
of vaccines and reproduction. Cryoport's proprietary Cryoport
Express® Shippers, Cryoportal™ Logistics Management
Platform, leading-edge SmartPak II™ Condition Monitoring System and
geo-sensing technology, paired with unparalleled cold chain
logistics expertise and 24/7 client support, make Cryoport the
end-to-end cold chain logistics partner that the industry
trusts.
Cryoport is dedicated to: simplifying global cold chain
logistics through innovative technology, unmatched monitoring and
data capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to follow
@cryoport on Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in
this news release which are not purely historical, including
statements regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the Company's SEC reports including,
but not limited to, the Company's 10-K for the year ended
December 31, 2017 filed with the SEC.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cryoport-opens-global-logistics-center-in-amsterdam-300784177.html
SOURCE Cryoport, Inc.